

Xiaomin Lu

Department of Biostatistics
College of Public Health and Health Professions
College of Medicine
2004 Mowry road, room 5234 CTRB
University of Florida
Gainesville, FL 32610

Phone: (352) 294-5915 or (352) 273-0568
Fax: (352) 294-5931
Email: xlu2@phhp.ufl.edu
WWW: <http://users.phhp.ufl.edu/xlu2/>

Degrees

Aug. 2007 Ph.D., Statistics (GPA 4.0/4.0), North Carolina State University
May 2005 M.S., Statistics (GPA 4.0/4.0), North Carolina State University
Aug. 2003 M.A., Mathematics (GPA 3.9/4.0), Central Michigan University
Jul. 1999 B.S., Applied Mathematics (GPA 88/100), South China University of Technology

Experience

Oct. 2013 – Research Assistant Professor, Department of Biostatistics
College of Public Health and Health Professions, College of Medicine, University of Florida

Nov. 2007 – Senior Statistician, Resource Statistician for Acute Lymphoblastic Leukemia (ALL) clinical trials in the Children's Oncology Group (COG) (Develop and submit new concepts for proposed pilot, Phase II and III clinical trials to NCI; Develop study design, determine sample size requirements, and safety and efficacy monitoring rules, and data collection elements; Perform interim analyses to monitor ongoing studies for patient enrollment, accrual targets, and safety with respect to observed toxicities and other adverse events; Generating biannual study progress reports and confidential data safety monitoring reports...)

Oct. 2010 – Sept. 2013 Assistant Professor, Department of Biostatistics
College of Public Health and Health Professions and Medicine, University of Florida

Jul. 2007 – Oct. 2010 Assistant Professor, Department of Epidemiology and Biostatistics
College of Public Health and Health Professions, University of Florida

Aug. 2006 – Jun. 2007 Research Assistant of Dr. Anastasios A.Tsiatis
Department of Statistics, North Carolina State University

May 2006 – Aug. 2006 Summer Intern, Vaccine BARDS, Merck Research Laboratory, North Wales, PA
(Two data analysis projects from clinical trials – HIV vaccine & sleep drug; Two applied research projects – Compare stratified rank-based tests & sensitivity analysis on selection bias from HIV vaccine)

Sep. 2004 – May 2006 Research Assistant of Dr. Anastasios A.Tsiatis

Department of Statistics, North Carolina State University
Aug. 2003 – Sep. 2004 Teaching Assistant, Department of Statistics
North Carolina State University
May 2002 – Jul. 2003 Data Mining Research Assistant
Center of Applied Research and Technology, Central Michigan University
(statistical analysis of two business projects using data mining applications)
Jul. 1998 – Oct. 1998 Programming Intern, YIDA Computer System CO. Ltd., Guangzhou, P.R. China
(Designed and implemented a retail selling system)

Honors and awards

2006 David P. Byar Young Investigator Travel Award
presented by the Biometrics section at the 2006 JSM, Seattle, WA
2005 Gertrude M. Cox Academic Achievement Award Outstanding Ph.D. Qualifier
2005 Elected to The National Statistical Honor Society of Mu Sigma Rho
2001 Doctoral Fellowship (renewed in 2002)
Mathematics Department, Central Michigan University
2001 Prize of Excellent Work as a First Year Graduate Student
Mathematics Department, Central Michigan University
1997 The First Prize of National Mathematical Contest of Modeling
1996 Excellent Undergraduate Student Award
Applied Mathematics Department, South China University of Technology
(I got this Award three times in 1996, 1997 and 1998, separately)

Research interests

Clinical trial designs, censored survival analysis, semiparametric methods with missing and censored data, longitudinal data analysis and causal inference

Teaching experience

Spring, 2008 - PHC 6050 (Online): Statistical Methods for Health Sciences I, University of Florida
Fall, 2008 - PHC 6050: Statistical Methods for Health Sciences I, University of Florida
Spring, 2009 - PHC 6050 (Online): Statistical Methods for Health Sciences I, University of Florida
Fall, 2009 - PHC 6050: Statistical Methods for Health Sciences I, University of Florida
Spring, 2010 - PHC 6050 (Online): Statistical Methods for Health Sciences I, University of Florida
Fall, 2010 - PHC 6050: Statistical Methods for Health Sciences I, University of Florida
Fall, 2011 - PHC 6020: Clinical Trials Methods, University of Florida
Fall, 2012 - PHC 6020: Clinical Trials Methods, University of Florida
Fall, 2012 - GMS 6861: Introduction to Biostatistics I, University of Florida
Fall, 2013 - GMS 6861: Introduction to Biostatistics I, University of Florida
Fall, 2014 - GMS 6861: Introduction to Biostatistics I, University of Florida

Graduate committee activities

Ph.D. Committee:

Co-Chair: Jing Liu (2013-2018, UF, Biostatistics)

Member: Qi An (2013-2016, UF, Biostatistics)
Li Li (2013-2016, UF, Biostatistics)
Helian Shanjun (2013-2016, UF, Biostatistics)
Yang Li (2011-16, UF, Biostatistics)
Zhulin He (2008-2012, UF, Biostatistics)
Yanping Wang (2008-2012, UF, Biostatistics)
Hao Zheng (2008-2012, UF, Biostatistics)
Zhuangyu Cai (2010-2014, UF, Biostatistics)
Ying He (2012-2014, UF, Biostatistics)
Hui Zeng (2012-2015, UF, Biostatistics)

External Member: Amal A. Wanigatunga (2013-2016, UF, Epidemiology)
Hui Hu (2013-2016, UF, Epidemiology)
Shahab Bozorgmehri (2012-16, UF, Epidemiology)
Claudia Lissaker (2012-2016, UF, Epidemiology)
Irene Murimi (2011-15, UF, Pharmacy Health Care Administration)
Shibasish Dasgupta (2009-2013, UF, Statistics)
Ayad Ali(2008-2012, UF, Pharmacy Health Care Administration)
Anqi Sun (2007-2011, UF, Statistics)
Dongwen Guo (2008-2011, UF, Pharmaceutical Outcomes and Policy)

M.P.H./M.S. Committee:

Chair: Zhongkai Wang (2014-2016, UF, Biostatistics)
Mansi Prasad (2012-2014, UF, Biostatistics)
Scott Gulig (2012-2014, UF, Biostatistics)
Heqiong Wang (2010-2012, UF, Biostatistics, M.P.H.)
Hsing Ju Tsai (2009-2011, UF, Biostatistics, M.P.H.)

Member: Yijing Ding (2014, UF, Biostatistics)
Justine M. Pierson (2014, UF, Biostatistics)
Hui Yan (2013, UF, Biostatistics)
Christine Seleski (2013, UF, Biostatistics)
Yi Zhang (2013,UF, Biostatistics)
Amanda Richards (2012, UF, Biostatistics)
Si Chen (2011, UF, Biostatistics)

Professional societies

American Statistical Association
International Biometric Society (ENAR)
Institute of Mathematical Statistics
Society for Clinical Trials

Departmental, university and national services

a. University

UF Health Cancer Center:

Member, Protocol Review and Monitoring Committee (PRMC), 2013 - present.

Member, Data and Safety Monitoring Committee (DSMC), 2013 - present.

b. College

Member, PHHP Curriculum Committee: 2011-present, College of Public Health and Health Profession, University of Florida

Member, PHHP Collaboration Committee: 2009-2011, College of Public Health and Health Profession, University of Florida

c. Department/Center

Member, Public Relations Committee: 2013-present, Department of Biostatistics, College of Public Health and Health Profession, University of Florida

Member, Clinical assistant professor of biostatistics search committee: 2010, College of Public Health and Health Profession, University of Florida

d. Profession

Member, Career Development Committee: 2015-present, American Statistical Association (ASA)

e. Children's Oncology Group

Member, Acute Lymphoblastic Leukemia (ALL) Steering Committee: 2008-present

Member, Statistics Discipline Committee: 2008-present

Grants and contracts

External fund

- 1U10CA180899-01 (Devidas), Children's Oncology Group Statistics and Data Center 3/1/2014 - 2/28/2019. **Co-investigator** on subcontract to University of Florida. 50% FTE.
- NIH/NCI U10 CA98413 (Anderson), Children's Oncology Group Statistics and Data Center 3/1/2008 - 2/28/2014. **Co-investigator** on subcontract to University of Florida. 50% FTE
- NIH/NCI 1U01 CA114762 (Willman), SPECS (Strategic Partnering To Evaluate Cancer Signatures) - Leukemia Signatures for Risk Classification and Targeting: Evaluation of Gene Expression Profiles for Risk Classification and Therapeutic Targeting in Acute Leukemia in Children and Adults, 7/1/2005-6/30/2010. **Co-investigator** on subcontract to University of Florida. 20% FTE.
- 2010- NIH / NINDS&NCMRR R01 NS050506 (Duncan), Locomotor Experience Applied Post-Stroke (LEAPS), 10/01/2010 - 06/30/2012. **Co-investigator** on subcontract to University of Florida. 30% FTE.
- FL DEPT OF HLTH BIOMED RES PGM/J&E KING 09KN-13 (Rose), Use of repetitive transcranial magnetic stimulation as an adjuvant to enhance post-stroke recovery, 7/1/2009 - 12/31/2012. **Co-investigator** on subcontract to University of Florida. 8% FTE.
- NIH/NICHD 3 U10 CA098543-03S1 (Reaman), BPCA (Best Pharmaceuticals in Children Act) - Methotrexate Neurotoxicity in children with ALL, 12/1/2005-2/28/2009. **Co-investigator** on subcontract to University of Florida. 30% FTE.

Internal fund

- UF Foundation UFF007084(Okunieff), Davis Cancer Research Equipment, 3/24/2006 - 3/14/2020. **Co-investigator**. 25% FTE.
- UF Research Foundation (Shuster), CTSI RDAPCORE Program, 4/1/2012 - 3/31/2014. **Co-investigator**. 10% FTE.

Publications

1) Refereed Journals

Theory and methods:

- 1.** **Lu, X.**, Sun, A. (g) and Wu, S. S. (2013) On estimating the mean of the selected normal population under the LINEX loss function in two-stage adaptive designs. *Journal of Statistical Planning and Inference*. Vol. 143, No. 7, pp. 1215-1220.
- 2.** **Lu, X.**, Mehrotra, D. V. and Shepherd, B. E. (2013) Rank-based principal stratum sensitivity analyses. *Statistics in Medicine*. doi: 10.1002/sim.5849.
- 3.** Brumback, B., Zheng, H., **Lu, X.**, Bouldin, E., Cannell, M. and Andresen, E. (2012) Doubly Robust Testing and Estimation of Model-Adjusted Effect-Measure Modification with Complex Survey Data. *Statistics in Medicine*. Vol. 32, No.4, pp.673-84.
- 4.** **Lu, X.** and Tsiatis, A. A. (2011) Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring. *Lifetime Data Analysis*. Vol.17, No.4, pp. 566-593.
- 5.** Mehrotra, D. V., **Lu, X.** and Li, X. (2010) Rank-Based Analyses of Stratified Experiments: Alternatives to the van Elteren Test. *The American Statistician*. Vol. 64, No. 2, 121-130.
- 6.** **Lu, X.** and Tsiatis, A. A. (2008) Improving the efficiency of the logrank test using auxiliary covariates. *Biometrika*. 95, 679-694.
- 7.** Tsiatis, A. A., Davidian M., Zhang M. and **Lu, X.** (2008) Covariate adjustment for two-stage treatment comparisons in randomized clinical trials: A principles yet flexible approach. Invited submission to *Statistics in Medicine* special issue on " Statistical methods in HIV/AIDS and its practical application." 27, 4658 - 4677.
- 8.** Lee, C. and **Lu, X.** (2005) Choice between partial least square and neural network predictive models. *International Journal of Computer and Information Science*. Vol. 6, No. 1, 31-37.

Collaborative:

- 9.** Nackers, L. M., Dubyak, P. J., **Lu, X.**, Dutton, G. R., Anton, S. D. and Perri, M. G. (2015) Group dynamics are associated with weight loss in behavioral treatment of obesity. Accepted *Obesity*.
- 10.** Wegman, M. P. (g), Guo, M. H. (g), Bennion, D. M., Shankar, M. N., Chrzanowski, S. M., Goldberg, L. A., Xu, J., Williams, T. A., **Lu, X.**, Hsu, S. I., Anton, S. D., Leeuwenburgh, C. and Brantly, M. L. (2015) Practicality of Intermittent Fasting and its Effect on Markers of Aging and Oxidative Stress. In Press *Rejuvenation Research*.
- 11.** Raetz, E. A., Cairo, M. S., Borowitz, M. J., **Lu, X.**, Devidas, M., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Zeng, H., Whitlock, J. A., Adamson, P. C., Hunger, S. P. and Carroll, W. L. (2015) Re-induction Chemotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Phase II Results from Childrens Oncology Group (COG) Study ADVL04P2. Accepted *Pediatric Blood and Cancer*.

- 12.** Lindemulder, S. J., Stork, L. C., Bostrom, B., **Lu, X.**, Devidas, M., Hunger, S., Neglia, J. P. and Kadan-Lottick, N. (2015) Standard risk (SR) acute lymphoblastic leukemia (ALL): a report from the children's oncology group (COG). In Press *Cancer*.
- 13.** Eldjerou, L. K., Cogle, C. R., Rosenau, E. H., **Lu, X.**, Bennett, C., Sugrue, M. W., Hoyne, J., Lambert, A., Ashley, L., Sazama, K., Wingard, J. R. and Zubair, A. C. (2015) Vitamin D Effect on Umbilical Cord Blood Characteristics: A Comparison between African Americans and Caucasians. In Press *Transfusion*.
- 14.** Alkhasawneh, A. (f), Reith, J. D., Toro, T. Z., Ayed, A., **Lu, X.**, George, T. and Duckworth, L. V. (2015) Interobserver Variability of Mitotic index and Utility of PHH3 for Risk Stratification in Gastrointestinal Stromal Tumors. *American Journal of Clinical Pathology*. Vol. 143, No. 3, pp. 385-92.
- 15.** Diouf, B., Crews, K. R., Lew, G., Pei, D., Cheng, C., Bao, J., Zheng, J., Yang, W., Fan, Y., Wheeler, H. E., Wing, C., Delaney, S. M., Komatsu, M., Paugh, S. W., McCorkel, J. R., **Lu, X.**, Winick, N. J., Carroll, W. L., Loh, M. L., Hunger, S. P., Devidas, M., Pui, C., Dolan, E., Relling, M. V. and Evans, W. E. (2015) Association of an inherited genetic variant with vincristine-1 related peripheral neuropathy in children with acute lymphoblastic leukemia. *Journal of the American Medical Association*. Vol. 313, No. 8, pp. 815-23.
- 16.** Ali, A. K. (g), Hartzema, A. G., Hendeles, L., **Lu, X.**, Winterstein, A. G. and Segal, R. (2015) Application of multi-category exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink (CPRD). *Value in Health*. Vol. 18, No. 2, pp. 260-70.
- 17.** Rose, D., Patten, C., McGuirk, T., **Lu, X.** and Triggs, W. J. (2014) Does Inhibitory Repetitive Transcranial Magnetic Stimulation Augment Functional Task Practice to Improve Arm Recovery in Chronic Stroke?. *Stroke Research and Treatment*. Vol. 2014. DOI: 10.1155/2014/305236
- 18.** Anton, S. D., Embry, C., Marsiske, M., **Lu, X.**, Doss, H., Leeuwenburgh, C. and Manini, T. M. (2014) Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. *Evidence-Based Complementary and Alternative Medicine*. Vol. 57, pp. 181-7, DOI: 10.1016/j.exger.2014.05.015.
- 19.** Myers, R. M. (g), Balsamo, L., **Lu, X.**, Devidas, M., Maloney, K. W., Carroll, W. L., Winick, N. J., Hunger, S. P. and Kadan-Lottick, N. S. (2014) A Prospective Study of Anxiety, Depression, and Behavioral Changes in the First Year after Diagnosis of Acute Lymphoblastic Leukemia. *Cancer*. Vol. 120, No. 9, pp. 1417-25.
- 20.** Boston, S. E., **Lu, X.**, Culp, W., TN., Montinaro, V., Romanelli, G., Dudley, R. M., Liptak, J. M., Mestrinho, L. A. and Buracco, P. (2014) Evaluation of Efficacy of Systemic Adjuvant Therapy for Canine Oral Malignant Melanoma after Surgical Excision: a VSSO Retrospective Study of 151 cases. *Journal of the American Veterinary Medical Association*. Vol. 245, No. 4, pp. 401-7.
- 21.** Roxanne, E., Lau, S., **Lu, X.**, Balsamo, L., Devidas, M., Winick, N., Hunger, S., Carroll, W., Maloney, K. and Kadan-Lottick, N. (2014) Family life events in the first year of acute lymphoblastic leukemia: a Childrens Oncology Group report. *Pediatric Blood and Cancer*. Vol. 61, No. 12, pp. 2277-84. doi: 10.1002/pbc.25195
- 22.** Hastings, C., Gaynon, P. S., Nachman, J. B., Sather, H. N., **Lu, X.**, Devidas, M. and Seibel, N. L. (2014) Increased post induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (>200 x 10⁹/L) with T cell Acute Lymphoblastic Leukemia but not B cell disease: A report from the Children's Oncology Group. *British Journal of Haematology*. Vol. 168, No. 4, pp. 533-46. DOI: 10.1111/bjh.13160
- 23.** Rose, D., Behrman, A., Nadeau, S. E., Martin, A. D., Schofield, R., Tilson, J. K., Cen, S. Y., **Lu, X.**, Wu, S. S., Azen, S., Duncan, P. (2013) Does Exercise Tolerance Testing at 60 days Post-Stroke Predict

Rehabilitation Performance? *Archives of Physical Medicine and Rehabilitation*. Vol. 94, No. 7, pp. 1223-9.

- 24.** Polcz, M. E., Adamson, L. A., **Lu, X.**, Chang, M. H., Fowler, L. J. and Hobbs, J. A. (2013) Increased IL-6 detection in adult and pediatric lymphoid tissue harboring Parvovirus B19. *Journal of Clinical Virology*. Vol. 57, No. 3, pp. 233-8.
- 25.** Kelly, M.E., **Lu, X.**, Devidas, M., Camitta, B., Abshire, T., Bernstein, M.L., Billett, A., Homans, A., Mandell, L., Ogden, A., Sandler, E. and Buchanan, G. (2013) Treatment of Relapsed Precursor-B Acute Lymphoblastic Leukemia With Intensive Chemotherapy: POG (Pediatric Oncology Group) Study 9411 (SIMAL 9). *Journal of Pediatric Hematology/Oncology*. Vol. 57, No. 7, pp. 509-513.
- 26.** Dobkin, B. H., Nadeau, S. E., Behrman, A. L., Wu, S. S., Rose, D., Bowden, M., Studenski, S., **Lu, X.** and Duncan, P. W. (2014) Prediction of responders for outcome measures of Locomotor Experience Applied Post Stroke trial. *Journal of Rehabilitation Research and Development*. Vol. 51, No. , pp. 39-50.
- 27.** Anton, S. D., **Lu, X.**, Heekin, K., Saha, D., Dubyak, P. and hausenblas, H.(2013) Effect of a Novel Dietary Supplement on pH Levels of Healthy Volunteers. *Journal of Integrative medicine*. Vol. 11, No. 6, pp. 384-8, doi: 10.3736/jintegrmed2013049.
- 28.** Hunger, S. P., **Lu, X.**, Devidas, M., Camitta, B. M., Gaynon, P. S., Winick, N. J., Reaman, G. H. and Carroll, W. L. (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia from 1990-2005: A Report from the Children' s Oncology Group. *Journal of Clinical Oncology*. Vol. 30, No. 14, 1663-9.
- 29.** Nadeau, S.E., **Lu, X.**, Dobkin, B., Wu, S.S., Dai, Y.E., and Duncan, P.W. (2012) A Prospective Test of the Late Effect of Potentially Anti-Neuroplastic Drugs in a Stroke Rehabilitation Study. *International Journal of Stroke*. doi:10.1111/j.1747-4949.2012.00920.x.
- 30.** Hunger, S. P., **Lu, X.**, Devidas, M., Camitta, B. M., Gaynon, P. S., Winick, N. J., Reaman, G. H. and Carroll, W. L. (2012) Reply to A. Bleyer et al. *Journal of Clinical Oncology*. Vol 30, No 32, 4038-9.
- 31.** Salzer, W. L., Winick, N. J., Wacker, P., **Lu, X.**, Devidas, M., Shuster, J. J., Mahoney, D. H., Lauer, S. J. and Camitta, B. M. (2011) Plasma Methotrexate, Red Blood Cell Methotrexate and Red Blood Cell Folate Levels and Outcome in Children with Precursor B Acute Lymphoblastic Leukemia: A Report from the Children' s Oncology Group. *Journal of Pediatric hematology/Oncology*. Vol. 34, No.2, e1-7.
- 32.** Atkins, A., Jacobson, E., Hernandez, J., Bolten, A. B. and **Lu, X.** (2010) Use of a Portable Point-of-Care (Vetscan Vs2) Biochemical Analyzer for Measuring Plasma Biochemical Levels in Free-Living Loggerhead Sea Turtles (Caretta). *Journal of Zoo and Wildlife Medicine*. Vol. 41, No. 4, pp. 585-593.

Manuscripts under review:

- 33.** Sliesoraitis, S., Leverence, R., Edwards, N. L., Lynch, J. W., Lim, D. C., **Lu, X.** and Allegra, C. (2015) Healthcare Provider Preferences for Second Line Palliative Chemotherapy. Submitted to *Journal of Pain and Symptom Management*.
- 34.** **Lu, X.**, He, Y. and Wu, S. (2015) Interval Estimation in Multi-stage Drop-the-losers Designs. Submitted to *Statistical Methods in Medical Research*.
- 35.** Delitto, D., Black, B. S., Cunningham, H. B., Sliesoraitis, S., **Lu, X.**, Liu, C., Sarosi, G. A., Thomas, R. M., Trevino, J. G., Hughes, S. J., George, T. and Behrns, K. E. (2015) Standardization of Surgical Care in a High-Volume Center Improves Survival in Resected Pancreatic Head Cancer. Revised and submitted to *Annals of Surgery*.

- 36.** Mitchell, H., **Lu, X.**, Myers, R., Sung, L., Balsamo, L., Carroll, W. L., Raetz, E., Loh, M. L., Mattano, L. A., Winick, N. J., Devidas, M., Hunger, S. P., Maloney, K. and Kadan-Lottick, N. S. (2015) Prospective, Longitudinal Assessment of Quality of Life in Children from Diagnosis to Three Months off Treatment for Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL): Results of Childrens Oncology Group Study AALL0331. In revision *International Journal of Cancer*.
- 37.** Delitto, D., Zhang, D., Han, S., Black, B., Knowlton, A., Vlada, A., Sarosi, G. A., Behrns, K. E., Thomas, R. M.x, **Lu, X.**, Liu, C., George, T., Hughes, S. J., Wallet, S. and Trevino, J. G.(2015) Nicotine reduces survival via augmentation of paracrine HGF-MET signaling in the pancreatic cancer microenvironment. Revised and submitted to *Clinical Cancer Research*.
- 38.** Niewerth, D., Kaspers, G. J. L., Jansen, G., van Meerloo, J., Zweegman, S., Jenkins, G., Whitlock, J. A., Hunger, S. P., **Lu, X.**, van de Ven, P. M., Horton, T. and Cloos, J. (2014) Ratios of immunoproteasome over constitutive proteasome expression are an indicator for sensitivity to bortezomib-containing reinduction chemotherapy in pediatric relapsed acute lymphocytic leukemia and acute myeloid leukemia. Submitted to *Clinical Cancer Research*.
- 39.** Alkhasawneh, A., Duckworth, L., Desai, N., **Lu, X.**, Sommerfeld, A., George, T. and Zuluaga-Toro, T. (2014) Clinical, Morphologic, and Immunophenotypic Characteristics of Ampullary Adenocarcinomas With An Emphasis on SMAD4 Expression. Revised and submitted to *American Journal of Surgical Pathology*.
- 40.** Chan, E., Duckworth, L. V., Alkhasawneh, A., Zuluaga-Toro, T., **Lu, X.**, Ben-David, K., Hughes, S. J., Rossidis, G., Zlotocki, R., Lightsey, J., Daily, K., Dang, L., Allegra, C., King, B. and George, T. J. (2014) HER2 Expression and Response to Neoadjuvant Chemoradiotherapy in Esophagogastric Adenocarcinoma. Revised and submitted to *The Oncologist*.

Manuscripts under preparation:

- 41.** **Lu, X.** and Chen, J. (2015) Exploiting auxiliary information to improve power for testing genetic effects on a binary outcome. To be submitted.
- 42.** **Lu, X.** and Chen, J. (2015) Exploiting auxiliary information to improve power for testing genetic effects on a right censored survival outcome. To be submitted.
- 43.** **Lu, X.**, Kairalla, J. A., Zeng, H. and Wu, S. S. (2015) Graphical Approach for 2×2 Factorial Designs. To be submitted.
- 44.** Dupuis, L. L., **Lu, X.**, Mitchel, H. R., Sung, L., Mattano, L. A., Carroll, W. L., Winick, N., Hunger, S. P., Maloney, K. W. and Kadan-Lottick, N. (2015) Anxiety, Pain, and Nausea during Treatment of Childhood Acute Lymphoblastic Leukemia: A Prospective, Longitudinal Study from the Children's Oncology Group.
- 45.** Kunin-Batson, A. S., **Lu, X.**, Balsamo, L., Graber, K., Devidas, M., Hunger, S. P., Carroll, W. L., Winick, N. J., Mattano, L., Maloney, K. W. and Kadan-Lottick, N. S. (2015) Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.
- 46.** Mitchel, H. R., **Lu, X.**, Myers, R., Sung, L., Balsamo, L., Carroll, W. L., Raetz, E., Loh, M. L., Mattano, L. A., Winick, N. J., Devidas, M., Hunger, S. P., Maloney, K. and Kadan-Lottick, N. S. (2015) Prospective, Longitudinal Assessment of Quality of Life in Children from Diagnosis to Three Months off Treatment for Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL): Results of Children's Oncology Group Study AALL0331

2) Refereed Abstract

1. Kim, J. T., Reith, J. D., **Lu, X.** and Shon, W. (2015) Clinicopathologic study of myxofibrosarcoma: a retrospective overview of the University of Florida cases. Submitted to *American Society for Clinical Pathology*.
2. Maloney, K. W., Angiolillo, A. L., Schore, R. J., Devidas, M., **Lu, X.**, Wang, C., Friedmann, A. M., Mattano, L. A. Jr., Loh, M. L., Raetz, E. A., Stork, L. C., Winick, N. J., Hunger, S. and Carroll, W. L. (2015) Intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration are associated with a low rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Childrens Oncology Group (COG) trials. Abstract submitted to *American Society of Clinical Oncology*.
3. George, T. J., Hasija, N., Ivey, A. M., Daily, K. C., Dang, L. H., Watson, S., Tormes, K., **Lu, X.**, Liu, C., Allegra, C. J., Behrns, K., Hughes, S. J., Kayaleh, O., Maddipatla, S., Bose, D., Thomas, S. S. and Trevino, J. G. (2015) Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma. Abstract submitted to *American Society of Clinical Oncology*.
4. George, T. J., Ivey, A. M., Hasija, N., Daily, K. C., Dang, L. H., Watson, S., Tormes, K., **Lu, X.**, Iqbal, A., Tan, S., Zendejas, I., Kayaleh, O., Maddipatla, S. and Allegra, C. J. (2015) Phase II study of sorafenib and capecitabine (SorCape) in RAS WT and mutated previously treated metastatic colorectal cancer. Abstract submitted to *American Society of Clinical Oncology*.
5. Sliesoraitis, S. (f), Collinsworth, A. L., Trevino, J. G., Hughes, S. J., Zlotecki, R., **Lu, X.**, Lightsey, J. L., Ivey, A. M., Allegra, C. J., Alkhasawneh, A., Dang, L. H., Daily, K. C., Behrns, K., Liu, C., Chauhan, S., Desai, N. V. and George, T. J. (2015) Neoadjuvant treatment with gemcitabine with nab-paclitaxel depletes SPARC and reduces Ki-67 in patients with resectable pancreatic adenocarcinoma. Selected for publication only *American Society of Clinical Oncology*.
6. Esiashvili, N., **Lu, X.**, Hunger, S., Merchant, T. E., Brown, P. A., Wall, D. A., Grupp, S. A. and Pulsipher, M. (2015) Higher lung dose received during total body irradiation for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia is associated with inferior progression-free and overall survival: A report from the Childrens Oncology Group. Selected for poster presentation *American Society of Clinical Oncology*.
7. George, T. J., Ivey, A. M., Daily, K. C., Dang, L. H., Watson, S., Granicz, R., Tormes, K., **Lu, X.**, Liu, C., Allegra, C. J., Behrns, K., Hughes, S. J., Ogunwobi, O. O., Thomas, S. S. and Trevino, J. G. (2014) Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma. Abstract submitted to *American Society of Clinical Oncology*.
8. George, T. J., Ivey, A. M., Daily, K. C., Dang, L. H., Watson, S., Granicz, R., McEwan, M. A., Scian, J., **Lu, X.**, Iqbal, A., Tan, S., Zendejas, I. and Allegra, C. J. (2014) Planned interim analysis of phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353. Abstract submitted to *American Society of Clinical Oncology*.
9. Lew, G., **Lu, X.**, Yanofsky, R., Rheingold, S. R., Whitlock, J., Gulig, S. D., Devidas, M., Pulsipher, M., Hastings, C. A., Winick, N. J., Carroll, W. L., Borowitz, M. J. and Hunger, S. (2014) The significance of minimal residual disease (MRD) in relapsed childhood b-lymphoblastic leukemia (B-ALL): A report from Childrens oncology group (COG) protocol AALL0433. Selected for oral presentation *American Society of Clinical Oncology*.
10. Sliesoraitis, S. (f), Desai, N. V., Trevino, J. G., Hughes, S. J., Zlotecki, R., Lightsey, J. L., Ivey, A. M., Allegra, C. J., Dang, L. H., Daily, K. C., Behrns, K., Liu, C., Chauhan, S., Collinsworth, A. L., **Lu, X.** and George, T. J. (2014) Final results for gemcitabine with nab-Paclitaxel (Abraxane) in neoadjuvant treatment of resectable pancreatic adenocarcinoma GAIN-1 study. Selected for E-publication *American Society of Clinical Oncology*.

- 11.** Kadan-Lottick, N. S., **Lu, X.**, Hockenberry, M., Whitley, M., Hunger, S., Devidas, M., Winick, N. J., Schore, R. J., Angiolillo, A. L. and Ness, K. K. (2014) Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard risk acute lymphoblastic leukemia (SR ALL): Results of Childrens oncology group (COG) AALL0932. Selected for poster presentation *American Society of Clinical Oncology*.
- 12.** Ali, A. K. (g), Winterstein, A., Hendeles, L., **Lu, X.**, Segal, R. and Hartzema, A. (2014) Comparison of rates of prescribing oral corticosteroids for asthma exacerbations between step-down therapy approaches among initiators of inhaled corticosteroids and long-acting beta-agonist combination therapy. *Journal of Allergy and Clinical Immunology*. February 2014; 133(2S):AB177 [Abstract No. 611].
- 13.** Sliesoraitis, S. (f), Collinsworth, A. L., Trevino, J. G., Zlotecki, R., **Lu, X.**, Lightsey, J. L., Allegra, C. J., Alkhasawneh, A., Dang, L. H., Daily, K. C., Behrns, K., Liu, C., Hughes, Ivey, A. M., S. J., Chauhan, S., Desai, N. V., and George, T. J. (2014) Neoadjuvant treatment with gemcitabine with nab-paclitaxel (Abraxane) depletes SPARC and reduces Ki-67 in patients with resectable pancreatic adenocarcinoma. Submitted to *Gastrointestinal Cancers Symposium*.
- 14.** Chang, M., Gonzalo, D. H., **Lu, X.** and Duckworth, L. V. (2014) Utility of CD123 for Diagnosing Low Grade Graft-Versus-Host Disease in the Stomach. Submitted to *United States and Canadian Academy of Pathology*.
- 15.** Huang, Y., Harris, B., **Lu, X.**, Liu, C. and Duckworth, L. V. (2014) c-Met Expression in Hepatocellular Carcinoma. Submitted to *United States and Canadian Academy of Pathology*.
- 16.** Alkhasawneh, A. (f), Duckworth, L. V., Desai, N., **Lu, X.**, Sommerfeld, A., George, T. and Toro, T. Z. (2013) Loss of SMAD4 Expression is a Poor Prognostic Factor in Ampullary Adenocarcinoma. Abstract accepted *United States and Canadian Academy of Pathology*.
- 17.** Chan, E. (f), George, T. J., Alkhasawneh, A. (f), Duckworth, L. V., Zuluaga-Toro, T., **Lu, X.** and Hughes, S. J. (2013) Expression relationships among EGFR family members and cmet in esophagogastric adenocarcinoma. Abstract submitted to *American Society of Clinical Oncology*.
- 18.** Duckworth, L.V., Alkhasawneh, A. (f), Desai, N., **Lu, X.**, Sommerfeld, A., George, T. and Toro, T. Z. (2013) Clinicopathologic Features of Ampullary Adenocarcinoma of Indeterminate Histologic Type (Non-Intestinal, Non-Biliary). *Modern pathology*. 26: 185a-186a.
- 19.** Alkhasawneh, A. (f), Duckworth, L. V., **Lu, X.**, George, T., Reith, J. and Toro, T. Z. (2013) Utility of pHH3 Immunohistochemistry In Risk Stratification of Gastrointestinal Stromal Tumors: an Interobserver Variability Study. Selected for poster presentation at *United States and Canadian Academy of Pathology*.
- 20.** Alkhasawneh, A. (f), Duckworth, L. V., Neelam Desai , Desai, N., **Lu, X.**, Sommerfeld, A., George, T. and Toro, T. Z. (2013) Immunohistochemical profile, clinical characteristics of ampullary adenocarcinoma of indeterminate histologic type (non-intestinal, non-biliary). Selected for poster presentation at *United States and Canadian Academy of Pathology*.
- 21.** Myers, R. M. (g), **Lu, X.**, Balsamo, L. M., Carroll, W., Hunger, S., Winick, N., Devidas, M., Maloney, K. and Kadan-Lottick, N. (2013) Prospective, longitudinal assessment of quality of life in children on active treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): a report from Children ' s Oncology Group (COG) AALL0331. Selected for poster presentation at *American Society of Pediatric Hematology/Oncology's*.
- 22.** Horton, T. M., **Lu, X.**, O' Brien, M. M., Borowitz, M. J., Devidas, M., Raetz, E. A., Brown, P. A., Zeng, H., Hunger, S. and Whitlock, J. (2013) Bortezomib reinduction therapy improves response rates in pediatric ALL in first relapse: A Childrens oncology group (COG) study (AALL07P1). Selected for oral presentation *American Society of Clinical Oncology*.

- 23.** Chan, E. (f), Alkhasawneh, A. (f), Duckworth, L. V., Zuluaga-Toro, T., **Lu, X.**, Hughes, S. J. and George, T. J. (2013) EGFR family and cmet expression profiles and prognostic significance in esophagogastric adenocarcinoma. Selected for E-publication *American Society of Clinical Oncology*.
- 24.** Duckworth, L. V., Chan, E. (f), Alkhasawneh, A. (f), Zuluaga-Toro, T., **Lu, X.**, Hughes, S. J. and George, T. J. (2013) HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. Selected for E-publication *American Society of Clinical Oncology*.
- 25.** Hunger, S. P., Devidas, M., Raetz, E. A., Loh, M. L., Winich, N. J., Carroll, W. L. and **Lu, X.** (2013) Improvements in overall survival (OS) in children with newly diagnosed acute lymphoblastic leukemia (ALL) enrolled in children' s oncology group (COG) trials in 2000-05 vs. 2006-09. Selected for oral presentation *International Society of Paediatric Oncology*.
- 26.** Ali, A. K. (g), Hartzema, A. G., Hendeles, L., **Lu, X.**, Winterstein, A. G., Segal, R. (2013) Long-Acting Beta-Agonists and Asthma Exacerbations Requiring Short Courses of Oral Corticosteroids: A Multi-Category Exposure Marginal Structural Models Analysis. *Value in Health*. 16(3), [Abstract No. PRS2].
- 27.** George, T. J., Ivey, A. M., Dang, L. H., Daily, K. C., Viviano, D. L., Watson, S., Granicz, R., McEwan, M. A., **Lu, X.**, and Allegra, C. J. (2013) Interim analysis of phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353. Abstract submitted to *American Society of Clinical Oncology*.
- 28.** George, T. J., Zlotecki, R., Trevino, J. G., Ivey, A. M., Desai, N. V., Allegra, C. J., Dang, L. H., Daily, K. C., Behrns, K., Viviano, D. L., Lightsey, J. L., Liu, C., Chauhan, S., Zuluaga-Toro, T., **Lu, X.** and Hughes, S. J.(2013) Gemcitabine with nab-paclitaxel (Abraxane) in neoadjuvant treatment of pancreatic adenocarcinoma GAIN-1 study. Abstract submitted to *American Society of Clinical Oncology*.
- 29.** George, T. J., Dang, L. H., Ivey, A. M., Daily, K. C., Allegra, C. J., Liu, C., Ogunwobi, O., Hughes, S. J., **Lu, X.**, Zajac-Kaye, M., Trevino, J. G. and Thomas, S. S. (2013) Phase II study of 5-fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma. Abstract submitted to American Society of Clinical Oncology.
- 30.** Duckworth, L. V., Harris, B., Salazar, E., **Lu, X.** and Liu, C. (2013) Quantitative Hep-Par 1 Expression As A Predictor For Progression To Hepatocellular Carcinoma. Abstract submitted to College of American Pathologists.
- 31.** Feely, M., Duckworth, L. V., Salazar, E., **Lu, X.** and Liu, C. (2013) Quantitative Analysis of Infiltrating T and B Lymphocytes in Hepatocellular Carcinoma Compared to Non-tumor Liver. Abstract submitted to College of American Pathologists.
- 32.** Diouf, B., Crews, K. R., Lew, G., Per, D., Cheng, C., Bao, J., Zheng, J., Yang, W., Fan, Y., Paugh, S., McCorkle, J. R., **Lu, X.**, Winick, N. J., Carroll, W. L., Loh, M. L., Hunger, S. P., Devidas, M., Pui, C., Relling, M. V. and Evans, W. E. (2013) Genome-wide association analyses identify susceptibility loci for vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Selected for oral presentation American Society of Hematology.
- 33.** Eldjerou, L., Rosenau, E.H., Bennett, C., Sugrue, M.W., **Lu, X.**, Sazama, K., Zubair, A. and Wingard, J.R. (2013) Vitamin D Effect on Umbilical Cord Blood Characteristics: A Comparison between African Americans and Caucasians. Selected for oral presentation to American Society of Hematology.
- 34.** Hsu, J. W., Shugurman, I., **Lu, X.**, Moreb, J. S. and Wingard, J. R. (2013) Effect of cumulative adverse clinical risk factors on patients with multiple myeloma undergoing first GCSF apheresis. Selected for poster presentation to American Society of Hematology.
- 35.** George, T. J., Ivey, A. M., Daily, K. C., Dang, L. H., Watson, S., Granicz, R., McEwan, M. A., Scian, J., **Lu, X.**, Iqbal, A., Tan, S., Zendejas, I. and Allegra, C. J.(2013) Planned interim analysis of phase II study

of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353. Selected for poster presentation Gastrointestinal Cancers Symposium.

- 36.** George, T. J., Ivey, A. M., Daily, K. C., Dang, L. H., Watson, S., Granicz, R., Tormes, K., **Lu, X.**, Liu, C., Allegra, C. J., Behrns, K., Hughes, S. J., Ogunwobi, O. O. and Trevino, J. G. (2013) Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in firstline metastatic pancreatic adenocarcinoma. Selected for poster presentation Gastrointestinal Cancers Symposium.
- 37.** Chan, E. (f), Alkhasawneh, A. (f), Duckworth, L. V., Zuluaga-Toro, T., **Lu, X.**, Hughes, S. J. and George, T. J. (2013) Expression relationships among EGFR family members and cmet in esophagogastric adenocarcinoma. Selected for poster presentation Gastrointestinal Cancers Symposium.
- 38.** Duckworth, L. V., Toro, T. Z., **Lu, X.** and Liu, C. (2013) Expression of Glutamine Synthetase in Cirrhosis and Potential Use as a Marker for Early Liver Cancer Diagnosis. Abstract accepted United States and Canadian Academy of Pathology.
- 39.** Alkhasawneh, A. (f), Chan, E., Toro, T. Z., **Lu, X.**, Hughes, S., George, T. and Duckworth, L. V. (2013) Comparison of C-met Immunoreactivity in Surgically Treated Gastroesophageal Adenocarcinoma Using Two Commercially Available Antibodies. Abstract accepted United States and Canadian Academy of Pathology.
- 40.** Niewerth, D., Kaspers, G. J. L., Jansen, G., van Meerloo, J., Zweegman, S., Jenkins, G., Whitlock, J. A., Hunger, S. P., **Lu, X.**, Cloos, J. and Horton, T. M. (2013) Ratios of Immunoproteasome over Constitutive Proteasome Expression are an Indicator for Sensitivity to Bortezomib-containing Reinduction Chemotherapy in Pediatric Relapsed Acute Lymphocytic Leukemia (ALL) and Acute Myeloid Leukemia (AML). Selected for poster presentation American Society of Hematology.
- 41.** Myers, R. M. (g), Balsamo, L., Carroll, W., Hunger, S., Winick, N., Devidas, M., **Lu, X.**, Maloney, K. and Kadan-Lottick, N. (2012) Emotional and behavioral functioning in the first year after diagnosis of standard risk (SR) acute lymphoblastic leukemia (ALL): a report from Children' s Oncology Group (COG) AALL0331. Selected for poster presentation at American Society of Pediatric Hematology/Oncology's.
- 42.** Lau, S., Balsamo, L., Devidas, M., **Lu, X.**, Winick, N., Hunger, S., Carroll, W., Maloney, K. and Kadan-Lottick, N. (2012) Family life events in the first year after diagnosis of standard risk (SR) acute lymphoblastic leukemia (ALL): a report from Children' s Oncology Group (COG) AALL0331. Selected for poster presentation at American Society of Pediatric Hematology/Oncology's.
- 43.** Lindemulder, S. J., Stork, L. C., Bostrom, B. C., **Lu, X.**, Devidas, M., Neglia, J. P. and Kadan-Lottick, N. (2012) Trends in body mass index (BMI) during and after treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): A report from the Children' s Oncology Group (COG). Selected for oral presentation in plenary session at American Society of Clinical Oncology.
- 44.** Anton, S., **Lu, X.**, Marsiske, M, Leeuwenburgh, C. and Manini, T. (2012) Resveratrol for Improved Performance in the Elderly: Safety Findings from the RIPE Trial. Abstract accepted International Resveratrol Conference.
- 45.** Patil, S., Jonkers, I., **Lu, X.** and Patten, C. (2011) Distinct Patterns of Walking Recovery Following Therapeutic Intervention Post-stroke: Responders vs. Non-Responders. Journal of Neurologic Physical Therapy (Combined Sections Meeting Neurology Section Poster Presentations), 35 (4): 213-223.
- 46.** Rose, D. K., Behrman, A. L., **Lu, X.**, Sullivan, K. J., Tilson, J. K., Martin, A., Schofield, R., Wu, S. S. and Duncan, P. W. (2011) Informing Locomotor Training Prescription Post-Stroke. Journal of Neurologic Physical Therapy(Combined Sections Meeting Neurology Section Poster Presentations), 35 (4): 213-223.
- 47.** Lew, G., Yanofsky, R., Winick, N., Rheingold, S., Jorstad, D., **Lu, X.**, Devidas, M., Whitlock, J., Hunger, S. and Carroll, W. (2011) Intensive Vincristine is Not Feasible in Intermediate-Risk Relapse of Childhood

Acute Lymphoblastic Leukemia (ALL): A Report from Children's Oncology Group Study AALL0433. Pediatric Blood Cancer (2011 ASPHO Abstract poster presentation), 56 (6): 897-973.

- 48.** Barredo, J. C., Hastings, C., **Lu, X.**, Marcus, R., Winick, N., Devidas, M., Whitlock, J., Ritchey, K. A., Hunger, S. and Carroll, W. (2011) Inferior Outcome with Reduced Dose Cranial Radiation (12 Gy) in Isolated CNS Relapse of All Treated with Intensive Systemic Chemotherapy: A Children's Oncology Group Study. Pediatric Blood Cancer (43rd Congress of the International Society of Paediatric Oncology (SIOP) 2011 Abstracts oral presentation), 57 (5): 705-897.
- 49.** Raetz, E. R., Cairo, M. S., Borowitz, M. J., **Lu, X.**, Devidas, M., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Whitlock, J. A., Adamson, P. C., Hunger, S. P. and Carroll, W. L. (2011) Reinduction chemoimmunotherapy with Epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in Children, adolescents and young adults: results from Children's Oncology Group (COG) study ADVL04P2. Blood (ASH Annual Meeting Abstracts Oral presentation), 118: 573a.

3) Non-refereed Publications

As Senior Statistician at the Children's Oncology Group (COG), I am responsible for providing biannual study progress reports (SPR) and confidential safety and efficacy monitoring reports for all clinical trials that I am involved in as trial statistician. The SPR contains detailed information on study accrual, progress of study conduct and toxicities. It is public and provided to the National Cancer Institute (NCI) and COG member institutions for their information, and also for submission to their local Institutional Review Boards (IRB). The corresponding confidential safety and efficacy monitoring report that contains very detailed outcome and toxicity information is provided to Data Safety Monitoring Committee (DSMC) for objective and independent monitoring for study efficacy, futility and safety, etc.,

- 1.** **Lu, X.**, Zeng, H. (Spring 2015) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood BPrecursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 2.** **Lu, X.**, Zeng, H., Lew, G. (Spring 2015) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood BPrecursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 3.** **Lu, X.**, Zeng, H., Terzah, H. M. (Fall 2014) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 4.** **Lu, X.**, Zeng, H. (Fall 2014) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 5.** **Lu, X.**, Wang, C. (Fall 2014) Data Safety Monitoring Committee Report: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).
- 6.** **Lu, X.**, Wang, C., Angiolillo, A. L., Schore, R. (Fall 2014) COG Study Progress Report: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).
- 7.** **Lu, X.**, Wang, C. (Spring 2014) Data Safety Monitoring Committee Report: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).

- 8.** Lu, X., Wang, C., Angiolillo, A. L., Schore, R. (Spring 2014) COG Study Progress Report: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).
- 9.** Lu, X., Zeng, H., Barredo, J. (Spring 2014) COG Study Progress Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 10.** Lu, X., Gulig, S. (Spring 2014) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 11.** Lu, X., Gulig, S., Lew, G. (Spring 2014) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 12.** Lu, X., Zeng, H. (Spring 2014) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 13.** Lu, X., Zeng, H., Terzah, H. M. (Spring 2014) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 14.** Lu, X., Zeng, H., Terzah, H. M. (Fall 2013) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 15.** Lu, X., Zeng, H. (Fall 2013) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 16.** Lu, X., Wang, C. (Fall 2013) Data Safety Monitoring Committee Report: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).
- 17.** Lu, X., Wang, C., Angiolillo, A. L., Schore, R. (Fall 2013) COG Study Progress Report: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).
- 18.** Lu, X., Zeng, H., Barredo, J. (Spring 2013) COG Study Progress Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 19.** Lu, X., Dai, Y. (Spring 2013) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 20.** Lu, X., Dai, Y., Lew, G. (Spring 2013) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 21.** Lu, X., Zeng, H. (Spring 2013) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction

Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

- 22.** Lu, X., Zeng, H., Raetz, E., J. (Spring 2013) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 23.** Lu, X., Zeng, H., Raetz, E., J. (Fall 2012) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 24.** Lu, X., Zeng, H. (Fall 2012) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 25.** Lu, X., Zeng, H., Raetz, E., J. (Fall 2012) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 26.** Lu, X., Zeng, H., Barredo, J. (Spring 2012) COG Study Progress Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 27.** Lu, X., Wang, C. (Spring 2012) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 28.** Lu, X., Wang, C., Lew, G. (Spring 2012) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 29.** Lu, X., Zeng, H. (Spring 2012) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 30.** Lu, X., Zeng, H., Raetz, E., J. (Spring 2012) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 31.** Lu, X., Zeng, H. (Spring 2012) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 32.** Lu, X., Zeng, H., Raetz, E., J. (Spring 2012) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 33.** Lu, X., Zeng, H. (Fall 2011) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 34.** Lu, X., Zeng, H., Raetz, E., J. (Fall 2011) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).

- 35.** Lu, X., Zeng, H. (Fall 2011) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 36.** Lu, X., Zeng, H., Raetz, E., J. (Fall 2011) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 37.** Lu, X., Zeng, H. (Spring 2011) Data Safety Monitoring Committee Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 38.** Lu, X., Zeng, H., Barredo, J. (Spring 2011) COG Study Progress Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 39.** Lu, X., Wang, C. (Spring 2011) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 40.** Lu, X., Wang, C., Lew, G. (Spring 2011) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 41.** Lu, X., Zeng, H. (Spring 2011) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 42.** Lu, X., Zeng, H., Raetz, E., J. (Spring 2011) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 43.** Lu, X., Zeng, H. (Spring 2011) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 44.** Lu, X., Zeng, H., Raetz, E., J. (Spring 2011) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 45.** Lu, X., Wang, Y., Lew, G. (Fall 2010) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 46.** Lu, X., Chen, R. (Fall 2010) Data Safety Monitoring Committee summary: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 47.** Lu, X., Chen, R. (Fall 2010) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 48.** Lu, X., Chen, R., Raetz, E., J. (Fall 2010) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).

- 49.** Lu, X., Wang, Y. (Fall 2010) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 50.** Lu, X., Wang, Y., Raetz, E., J. (Fall 2010) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 51.** Lu, X., Wang, Y. (Spring 2010) Data Safety Monitoring Committee Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 52.** Lu, X., Wang, Y., Barredo, J. (Spring 2010) COG Study Progress Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 53.** Lu, X., Wang, Y. (Spring 2010) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 54.** Lu, X., Wang, Y., Lew, G. (Spring 2010) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 55.** Lu, X., Wang, Y. (Spring 2010) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 56.** Lu, X., Wang, Y., Raetz, E., J. (Spring 2010) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 57.** Lu, X., Wang, Y. (Spring 2010) Data Safety Monitoring Committee Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 58.** Lu, X., Wang, Y., Raetz, E., J. (Spring 2010) COG Study Progress Report: AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND#58, 443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
- 59.** Lu, X., Wang, Y., Lew, G. (Fall 2009) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 60.** Lu, X., Chen, R. (Fall 2009) Data Safety Monitoring Committee summary: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 61.** Lu, X., Chen, R. (Fall 2009) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).

- 62. Lu, X.,** Chen, R., Raetz, E., J. (Fall 2009) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 63. Lu, X.,** Wang, Y. (Spring 2009) Data Safety Monitoring Committee Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 64. Lu, X.,** Wang, Y., Barredo, J. (Spring 2009) COG Study Progress Report: AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 \geq 18 months).
- 65. Lu, X.,** Wang, Y. (Spring 2009) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 66. Lu, X.,** Wang, Y., Lew, G. (Spring 2009) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 67. Lu, X.,** Wang, Y. (Spring 2009) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 68. Lu, X.,** Wang, Y., Raetz, E., J. (Spring 2009) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 69. Lu, X.,** Chen, R. (Fall 2008) Data Safety Monitoring Committee Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 70. Lu, X.,** Chen, R., Lew, G. (Fall 2008) COG Study Progress Report: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies.
- 71. Lu, X.,** Chen, R. (Fall 2008) Data Safety Monitoring Committee Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).
- 72. Lu, X.,** Chen, R., Raetz, E., J. (Fall 2008) COG Study Progress Report: ADVL04P2, A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL).

Invited presentations

- 1. Lu, X.** and Chen, J. (2013) Exploiting Auxiliary information to improve power for testing genetic effects with binary or time-to-event data. Department of Statistics, North Carolina State University, Raleigh, NC.
- 2. Lu, X.** and Tsiatis, A. A. (2013) Semiparametric Estimation of Treatment Effect with Time-Lagged Response in the Presence of Informative Censoring. Joint Statistical Meetings (JSM), Montreal, QC, Canada.
- 3. Lu, X.,** Devidas, M. and Whitlock, J. A. (2010) Sequential randomized phase II screening trials. Rare Paediatric Tumour Clinical Trial Design Workshop, Birmingham, UK.

- 4.** **Lu, X.** and Tsiatis, A. A. (2011) Improving the efficiency of the log-rank test using auxiliary covariates. Johnson and Johnson Pharmaceutical Research and Development, L.L.C., New Brunswick, NJ.
- 5.** **Lu, X.** and Tsiatis, A. A. (2009) Improving the efficiency of the log-rank test using auxiliary covariates. Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC.
- 6.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. Department of Epidemiology and Biostatistics, University of Florida, Gainesville, FL.
- 7.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH.
- 8.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.
- 9.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. Department of Epidemiology and Biostatistics, University of Florida, Gainesville, FL.
- 10.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA.
- 11.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. Health Administration, Biostatistics, and Epidemiology, University of Georgia, Athens, GA.
- 12.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. Department of Biostatistics, University of Wisconsin at Madison, Madison, WI.
- 13.** **Lu, X.** and Mehrotra, D. V. (2006) Comparing stratified rank-based tests. Biostatistics and Research Decision Sciences (BARDS) department, Merck Research Laboratories, North Wales, PA.

Contributed presentations

- 1.** Lew, G., **Lu, X.**, Yanofsky, R., Rheingold, S. R., Whitlock, J., Gulig, S. D., Devidas, M., Pulsipher, M., Hastings, C. A., Winick, N. J., Carroll, W. L., Borowitz, M. J. and Hunger, S. (2014) The significance of minimal residual disease (MRD) in relapsed childhood b-lymphoblastic leukemia (B-ALL): A report from Childrens oncology group (COG) protocol AALL0433. Oral presentation at the 2014 annual meeting of *American Society of Clinical Oncology*.
- 2.** Kadan-Lottick, N. S., **Lu, X.**, Hockenberry, M., Whitley, M., Hunger, S., Devidas, M., Winick, N. J., Schore, R. J., Angiolillo, A. L. and Ness, K. K. (2014) Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard risk acute lymphoblastic leukemia (SR ALL): Results of Childrens oncology group (COG) AALL0932. Poster presentation at the 2014 annual meeting of *American Society of Clinical Oncology*.
- 3.** Alkhasawneh, A., Duckworth, L. V., Desai, N., **Lu, X.**, Sommerfeld, A., George, T. and Toro, T. Z. (2013) Loss of SMAD4 Expression is a Poor Prognostic Factor in Ampullary Adenocarcinoma. Poster presentation at the 102nd annual meeting of *United States and Canadian Academy of Pathology*.
- 4.** Duckworth, L.V., Alkhasawneh, A., Desai, N., **Lu, X.**, Sommerfeld, A., George, T. and Toro, T. Z. (2013) Clinicopathologic Features of Ampullary Adenocarcinoma of Indeterminate Histologic Type (Non-Intestinal, Non-Biliary). Poster presentation at the 102nd annual meeting of *United States and Canadian Academy of Pathology*.

- 5.** Alkhasawneh, A., Duckworth, L. V., **Lu, X.**, George, T., Reith, J. and Toro, T. Z. (2013) Utility of pHH3 Immunohistochemistry In Risk Stratification of Gastrointestinal Stromal Tumors: an Inter-observer Variability Study. Poster presentation at the 102nd annual meeting of United States and Canadian Academy of Pathology.
- 6.** Alkhasawneh, A., Duckworth, L. V., Neelam Desai , Desai, N., **Lu, X.**, Sommerfeld, A., George, T. and Toro, T. Z. (2013) Immunohistochemical profile, clinical characteristics of ampullary adenocarcinoma of indeterminate histologic type (non-intestinal, on-biliary). Poster presentation at the 102nd annual meeting of *United States and Canadian Academy of Pathology*.
- 7.** Myers, R. M., **Lu, X.**, Balsamo, L. M., Carroll, W., Hunger, S., Winick, N., Devidas, M., Maloney, K. and Kadan-Lottick, N. (2013) Prospective, longitudinal assessment of quality of life in children on active treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): a report from Children ' s Oncology Group (COG) AALL0331. Poster presentation at the 26th annual meeting of *American Society of Pediatric Hematology/Oncology ' s*.
- 8.** Horton, T. M., **Lu, X.**, O ' Brien, M. M., Borowitz, M. J., Devidas, M., Raetz, E. A., Brown, P. A., Zeng, H., Hunger, S. and James Whitlock (2013) Bortezomib reinduction therapy improves response rates in pediatric ALL in first relapse: A Childrens oncology group (COG) study (AALL07P1). Oral presentation at the 2013 annual meeting of *American Society of Clinical Oncology*.
- 9.** Myers, R. M., Balsamo, L., Carroll, W., Hunger, S., Winick, N., Devidas, M., **Lu, X.**, Maloney, K. and Kadan-Lottick, N. (2012) Emotional and behavioral functioning in the first year after diagnosis of standard risk (SR) acute lymphoblastic leukemia (ALL): a report from Children ' s Oncology Group (COG) AALL0331. Poster presentation at the 25th annual meeting of *American Society of Pediatric Hematology/Oncology ' s*.
- 10.** Lau, S., Balsamo, L., Devidas, M., **Lu, X.**, Winick, N., Hunger, S., Carroll, W., Maloney, K. and Kadan-Lottick, N. (2012) Family life events in the first year after diagnosis of standard risk (SR) acute lymphoblastic leukemia (ALL): a report from Children ' s Oncology Group (COG) AALL0331. Poster presentation at the 25th annual meeting of *American Society of Pediatric Hematology/Oncology ' s*.
- 11.** Lindemulder, S. J., Stork, L. C., Bostrom, B. C., **Lu, X.**, Devidas, M., Neglia, J. P. and Kadan-Lottick, N. (2012) Trends in body mass index (BMI) during and after treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): A report from the Children ' s Oncology Group (COG). Oral presentation at the 47th annual meeting of the *American Society of Clinical Oncology*.
- 12.** Anton, S., **Lu, X.**, Marsiske, M, Leeuwenburgh, C. and Manini, T. (2012) Resveratrol for Improved Performance in the Elderly: Safety Findings from the RIPE Trial. Oral presentation at the *International Resveratrol Conference*.
- 13.** Rose, D.K., Behrman, A.L., **Lu, X.**, Sullivan, K.J., Tilson, J.K., Martin, A., Schofield, R., Wu, S.S., Duncan and P.W. (2012). Presentation at the *American Physical Therapy Association, Combined Sections Meeting*, Chicago, IL, Feb. 11, 2012.
- 14.** Patil, S., Jonkers, I, **Lu, X.** and Patten, C. (2012) Distinct Patterns of Walking Recovery Following Therapeutic Intervention Post-stroke: Responders vs. Non-Responders. Presentation at the *American Physical Therapy Association, Combined Sections Meeting*, Chicago, IL, Feb. 11, 2012.
- 15.** **Lu, X.** and Devidas, M. (2011) Sequential Randomized Phase II Clinical Trial. 32nd Annual Meeting of the Society for Clinical Trials, Vancouver, British Columbia, Canada.
- 16.** Lew, G., Yanofsky, R., Winick, N., Rheingold, S., Jorstad, D., **Lu, X.**, Devidas, M., Whitlock, J., Hunger, S. and Carroll, W. (2011) Intensive Vincristine is Not Feasible in Intermediate-Risk Relapse of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from Children ' s Oncology Group Study AALL0433.

Poster presentation at the 24th annual meeting of the *American Society of Pediatric Hematology/Oncology*, Baltimore, MD.

- 17.** Barredo, J. C., Hastings, C., **Lu, X.**, Marcus, R., Winick, N., Devidas, M., Whitlock, J., Ritchey, K.A., Hunger, S. and Carroll, W. (2011) Inferior Outcome with Reduced Dose Cranial Radiation (12 Gy) in Isolated CNS Relapse of All Treated with Intensive Systemic Chemotherapy: A Children' s Oncology Group Study. Poster presentation at the 43rd congress of the *International Society of Pediatric Oncology*, Auckland, New Zealand.
- 18.** Raetz, E. R., Cairo, M. S., Borowitz, M. J., **Lu, X.**, Devidas, M., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Whitlock, J. A., Adamson, P. C., Hunger, S. P. and Carroll, W. L. (2011) Reinduction chemoimmunotherapy with Epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in Children, adolescents and young adults: results from Children' s Oncology Group (COG) study ADVL04P2. Oral presentation at the 53rd annual meeting of the *American Society of Hematology*, San Diego, CA.
- 19.** **Lu, X.** and Tsiatis, A. A. (2010) Semiparametric Estimation of Treatment Effect with Time-Lagged Response in the Presence of Informative Censoring. *ENAR*, New Orleans, LA.
- 20.** **Lu, X.** and Tsiatis, A. A. (2009) Semiparametric Estimation of Treatment Effect with Time-Lagged Response in the Presence of Informative Censoring. *ENAR*, San Antonio, TX.
- 21.** **Lu, X.** and Tsiatis, A. A. (2007) Improving the efficiency of the log-rank test using auxiliary covariates. *ENAR*, Atlanta, GA.
- 22.** **Lu, X.** and Tsiatis, A. A. (2006) Improving the efficiency of the log-rank test using auxiliary covariates. Joint Statistical Meetings (JSM), Seattle, WA.
- 23.** Mehrotra, D. V., **Lu, X.** and Li, X. (2007) Efficient Rank-Based Inference for Stratified Trials. Midwest Biopharmaceutical Statistics Workshop, Muncie, IN.